The Manufacturers Life Insurance Company bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 168,857 shares of the company’s stock, valued at approximately $4,096,000. The Manufacturers Life Insurance Company owned approximately 0.16% of Nurix Therapeutics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Polymer Capital Management HK LTD acquired a new position in shares of Nurix Therapeutics during the second quarter worth $1,429,000. EP Wealth Advisors LLC acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $214,000. Ieq Capital LLC acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $252,000. E Fund Management Co. Ltd. bought a new stake in Nurix Therapeutics during the 2nd quarter worth $234,000. Finally, Edmond DE Rothschild Holding S.A. bought a new stake in Nurix Therapeutics during the 2nd quarter worth $2,183,000.
Nurix Therapeutics Stock Performance
Nurix Therapeutics stock opened at $26.04 on Wednesday. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -7.55 and a beta of 1.80. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $28.23. The stock’s 50 day moving average price is $24.65 and its two-hundred day moving average price is $19.14.
Insider Buying and Selling at Nurix Therapeutics
In other news, CFO Houte Hans Van sold 4,761 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at $978,443.76. This represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 1,452 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the completion of the transaction, the insider owned 117,227 shares in the company, valued at approximately $2,985,771.69. This represents a 1.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 26,766 shares of company stock valued at $626,343. Insiders own 6.70% of the company’s stock.
Analysts Set New Price Targets
Several research firms have commented on NRIX. Morgan Stanley increased their target price on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Truist Financial upped their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Royal Bank Of Canada lifted their target price on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Finally, UBS Group boosted their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $34.21.
Check Out Our Latest Report on NRIX
About Nurix Therapeutics
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Featured Articles
- Five stocks we like better than Nurix Therapeutics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
